An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity

[1]  J. Köllermann,et al.  Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis , 2023, Journal of Translational Medicine.

[2]  M. Cheng,et al.  A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity , 2022, Journal of Translational Medicine.

[3]  M. Cheng,et al.  A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity , 2022, Journal of translational medicine.

[4]  Lieping Chen,et al.  Resistance Mechanisms to Anti-PD Cancer Immunotherapy. , 2022, Annual review of immunology.

[5]  Xueda Hu,et al.  Immune phenotypic linkage between colorectal cancer and liver metastasis. , 2022, Cancer cell.

[6]  F. Ghiringhelli,et al.  Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer , 2021, Cancer Immunology and Immunotherapy.

[7]  E. Di Carlo,et al.  Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival , 2021, Frontiers in Immunology.

[8]  M. Zhang,et al.  Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity , 2021, Nature Communications.

[9]  Shih-Hsun Chen,et al.  Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity , 2021, Journal for ImmunoTherapy of Cancer.

[10]  J. Wolchok,et al.  Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways , 2021, Nature Reviews Clinical Oncology.

[11]  Miguel Ángel Martínez,et al.  A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade , 2021, Nature Communications.

[12]  Miguel Ángel Martínez,et al.  A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade , 2021, Nature communications.

[13]  M. Cragg,et al.  TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity , 2021, Communications biology.

[14]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[15]  F. Spiga,et al.  Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade , 2021, Oncoimmunology.

[16]  Inkyung Jung,et al.  4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers , 2020, Journal for ImmunoTherapy of Cancer.

[17]  E. Engleman,et al.  Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. , 2020, Annual review of pathology.

[18]  L. Boon,et al.  The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. , 2020, Cancer cell.

[19]  M. Dhodapkar,et al.  Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. , 2020, JCI insight.

[20]  Sarah Batey,et al.  FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models , 2020, Clinical Cancer Research.

[21]  M. Yousefi,et al.  Targeting the 4-1BB costimulatory molecule through single chain antibodies promotes the human T-cell response , 2020, Cellular & Molecular Biology Letters.

[22]  Michael M. Schmidt,et al.  Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. , 2020, JCI insight.

[23]  G. Gao,et al.  Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy , 2020, Proceedings of the National Academy of Sciences.

[24]  C. Klein,et al.  Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy , 2020, Science Translational Medicine.

[25]  Craig B. Davis,et al.  First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas , 2020, Clinical Cancer Research.

[26]  J. Lee,et al.  Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. , 2020, Cancer letters.

[27]  A. Thakur,et al.  Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity , 2020, Molecular Cancer Therapeutics.

[28]  P. Fecci,et al.  4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers , 2019, Clinical Cancer Research.

[29]  Young Seok Ju,et al.  4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8+ T Cells in Hepatocellular Carcinoma , 2019, Hepatology.

[30]  C. Klein,et al.  Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy , 2019, Science Translational Medicine.

[31]  L. Matis,et al.  Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343 , 2019, Clinical Cancer Research.

[32]  R. Blelloch,et al.  Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory , 2019, Cell.

[33]  B. Frendéus,et al.  Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB , 2019, Front. Immunol..

[34]  A. Nager,et al.  Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab , 2018, Nature Communications.

[35]  G. Gao,et al.  Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. , 2018, Cell reports.

[36]  M. Croft,et al.  Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier , 2018, The Journal of Biological Chemistry.

[37]  Simon C Watkins,et al.  4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses , 2018, The Journal of experimental medicine.

[38]  Craig B. Davis,et al.  Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer , 2018, Clinical Cancer Research.

[39]  Manu Sebastian,et al.  Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway , 2018, Clinical Cancer Research.

[40]  D. Faustman,et al.  Structural principles of tumor necrosis factor superfamily signaling , 2018, Science Signaling.

[41]  E. Schmidt,et al.  Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors , 2017, Clinical Cancer Research.

[42]  G. Babiera,et al.  4-1BB–Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells , 2017, Cancer Immunology Research.

[43]  R. Levy,et al.  Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody , 2016, Clinical Cancer Research.

[44]  Rachel E Rigsby,et al.  Using the PyMOL application to reinforce visual understanding of protein structure , 2016, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.

[45]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[46]  A. Korman,et al.  FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. , 2015, Cancer cell.

[47]  Craig B. Davis,et al.  A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. , 2014 .

[48]  P. Ascierto,et al.  Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination , 2013, Clinical Cancer Research.

[49]  J. Wolchok,et al.  Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells , 2013, Clinical Cancer Research.

[50]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[51]  P. Bruhns,et al.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.

[52]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[53]  P. Kufer,et al.  Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. , 2006, Molecular immunology.

[54]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination , 2022 .

[55]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[56]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.